Potent immune modulation by medi6383, an engineered human ox40 ligand igg4p fc fusion protein

Michael D. Oberst, Catherine Auge, Chad Morris, Stacy Kentner, Kathy Mulgrew, Kelly McGlinchey, James Hair, Shino Hanabuchi, Qun Du, Melissa Damschroder, Hui Feng, Steven Eck, Nicholas Buss, Lolke de Haan, Andrew J. Pierce, Haesun Park, Andrew Sylwester, Michael Axthelm, Louis Picker, Nicholas P. Morris & 2 others Andrew Weinberg, Scott A. Hammond

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Ligation of OX40 (CD134, TNFRSF4) on activated T cells by its natural ligand (OX40L, CD252, TNFSF4) enhances cellular survival, proliferation, and effector functions such as cytokine release and cellular cytotoxicity. We engineered a recombinant human OX40L IgG4P Fc fusion protein termed MEDI6383 that assembles into a hexameric structure and exerts potent agonist activity following engagement of OX40. MEDI6383 displayed solution-phase agonist activity that was enhanced when the fusion protein was clustered by Fc gamma receptors (FcgRs) on the surface of adjacent cells. The resulting costimulation of OX40 on T cells induced NFkB promoter activity in OX40-expressing T cells and induced Th1-type cytokine production, proliferation, and resistance to regulatory T cell (Treg)mediated suppression. MEDI6383 enhanced the cytolytic activity of tumor-reactive T cells and reduced tumor growth in the context of an alloreactive human T cell:tumor cell admix model in immunocompromised mice. Consistent with the role of OX40 costimulation in the expansion of memory T cells, MEDI6383 administered to healthy nonhuman primates elicited peripheral blood CD4 and CD8 central and effector memory T-cell proliferation as well as B-cell proliferation. Together, these results suggest that OX40 agonism has the potential to enhance antitumor immunity in human malignancies.

Original languageEnglish (US)
Pages (from-to)1024-1038
Number of pages15
JournalMolecular Cancer Therapeutics
Volume17
Issue number5
DOIs
StatePublished - May 1 2018

Fingerprint

T-Lymphocytes
Proteins
Cell Proliferation
Neoplasms
Cytokines
IgG Receptors
Regulatory T-Lymphocytes
human TNFSF4 protein
Primates
Ligation
Immunity
B-Lymphocytes
Ligands
Survival
Growth

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Oberst, M. D., Auge, C., Morris, C., Kentner, S., Mulgrew, K., McGlinchey, K., ... Hammond, S. A. (2018). Potent immune modulation by medi6383, an engineered human ox40 ligand igg4p fc fusion protein. Molecular Cancer Therapeutics, 17(5), 1024-1038. https://doi.org/10.1158/1535-7163.MCT-17-0200

Potent immune modulation by medi6383, an engineered human ox40 ligand igg4p fc fusion protein. / Oberst, Michael D.; Auge, Catherine; Morris, Chad; Kentner, Stacy; Mulgrew, Kathy; McGlinchey, Kelly; Hair, James; Hanabuchi, Shino; Du, Qun; Damschroder, Melissa; Feng, Hui; Eck, Steven; Buss, Nicholas; de Haan, Lolke; Pierce, Andrew J.; Park, Haesun; Sylwester, Andrew; Axthelm, Michael; Picker, Louis; Morris, Nicholas P.; Weinberg, Andrew; Hammond, Scott A.

In: Molecular Cancer Therapeutics, Vol. 17, No. 5, 01.05.2018, p. 1024-1038.

Research output: Contribution to journalArticle

Oberst, MD, Auge, C, Morris, C, Kentner, S, Mulgrew, K, McGlinchey, K, Hair, J, Hanabuchi, S, Du, Q, Damschroder, M, Feng, H, Eck, S, Buss, N, de Haan, L, Pierce, AJ, Park, H, Sylwester, A, Axthelm, M, Picker, L, Morris, NP, Weinberg, A & Hammond, SA 2018, 'Potent immune modulation by medi6383, an engineered human ox40 ligand igg4p fc fusion protein', Molecular Cancer Therapeutics, vol. 17, no. 5, pp. 1024-1038. https://doi.org/10.1158/1535-7163.MCT-17-0200
Oberst, Michael D. ; Auge, Catherine ; Morris, Chad ; Kentner, Stacy ; Mulgrew, Kathy ; McGlinchey, Kelly ; Hair, James ; Hanabuchi, Shino ; Du, Qun ; Damschroder, Melissa ; Feng, Hui ; Eck, Steven ; Buss, Nicholas ; de Haan, Lolke ; Pierce, Andrew J. ; Park, Haesun ; Sylwester, Andrew ; Axthelm, Michael ; Picker, Louis ; Morris, Nicholas P. ; Weinberg, Andrew ; Hammond, Scott A. / Potent immune modulation by medi6383, an engineered human ox40 ligand igg4p fc fusion protein. In: Molecular Cancer Therapeutics. 2018 ; Vol. 17, No. 5. pp. 1024-1038.
@article{33f770267dfe4c23adc62840d27e52c7,
title = "Potent immune modulation by medi6383, an engineered human ox40 ligand igg4p fc fusion protein",
abstract = "Ligation of OX40 (CD134, TNFRSF4) on activated T cells by its natural ligand (OX40L, CD252, TNFSF4) enhances cellular survival, proliferation, and effector functions such as cytokine release and cellular cytotoxicity. We engineered a recombinant human OX40L IgG4P Fc fusion protein termed MEDI6383 that assembles into a hexameric structure and exerts potent agonist activity following engagement of OX40. MEDI6383 displayed solution-phase agonist activity that was enhanced when the fusion protein was clustered by Fc gamma receptors (FcgRs) on the surface of adjacent cells. The resulting costimulation of OX40 on T cells induced NFkB promoter activity in OX40-expressing T cells and induced Th1-type cytokine production, proliferation, and resistance to regulatory T cell (Treg)mediated suppression. MEDI6383 enhanced the cytolytic activity of tumor-reactive T cells and reduced tumor growth in the context of an alloreactive human T cell:tumor cell admix model in immunocompromised mice. Consistent with the role of OX40 costimulation in the expansion of memory T cells, MEDI6383 administered to healthy nonhuman primates elicited peripheral blood CD4 and CD8 central and effector memory T-cell proliferation as well as B-cell proliferation. Together, these results suggest that OX40 agonism has the potential to enhance antitumor immunity in human malignancies.",
author = "Oberst, {Michael D.} and Catherine Auge and Chad Morris and Stacy Kentner and Kathy Mulgrew and Kelly McGlinchey and James Hair and Shino Hanabuchi and Qun Du and Melissa Damschroder and Hui Feng and Steven Eck and Nicholas Buss and {de Haan}, Lolke and Pierce, {Andrew J.} and Haesun Park and Andrew Sylwester and Michael Axthelm and Louis Picker and Morris, {Nicholas P.} and Andrew Weinberg and Hammond, {Scott A.}",
year = "2018",
month = "5",
day = "1",
doi = "10.1158/1535-7163.MCT-17-0200",
language = "English (US)",
volume = "17",
pages = "1024--1038",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "5",

}

TY - JOUR

T1 - Potent immune modulation by medi6383, an engineered human ox40 ligand igg4p fc fusion protein

AU - Oberst, Michael D.

AU - Auge, Catherine

AU - Morris, Chad

AU - Kentner, Stacy

AU - Mulgrew, Kathy

AU - McGlinchey, Kelly

AU - Hair, James

AU - Hanabuchi, Shino

AU - Du, Qun

AU - Damschroder, Melissa

AU - Feng, Hui

AU - Eck, Steven

AU - Buss, Nicholas

AU - de Haan, Lolke

AU - Pierce, Andrew J.

AU - Park, Haesun

AU - Sylwester, Andrew

AU - Axthelm, Michael

AU - Picker, Louis

AU - Morris, Nicholas P.

AU - Weinberg, Andrew

AU - Hammond, Scott A.

PY - 2018/5/1

Y1 - 2018/5/1

N2 - Ligation of OX40 (CD134, TNFRSF4) on activated T cells by its natural ligand (OX40L, CD252, TNFSF4) enhances cellular survival, proliferation, and effector functions such as cytokine release and cellular cytotoxicity. We engineered a recombinant human OX40L IgG4P Fc fusion protein termed MEDI6383 that assembles into a hexameric structure and exerts potent agonist activity following engagement of OX40. MEDI6383 displayed solution-phase agonist activity that was enhanced when the fusion protein was clustered by Fc gamma receptors (FcgRs) on the surface of adjacent cells. The resulting costimulation of OX40 on T cells induced NFkB promoter activity in OX40-expressing T cells and induced Th1-type cytokine production, proliferation, and resistance to regulatory T cell (Treg)mediated suppression. MEDI6383 enhanced the cytolytic activity of tumor-reactive T cells and reduced tumor growth in the context of an alloreactive human T cell:tumor cell admix model in immunocompromised mice. Consistent with the role of OX40 costimulation in the expansion of memory T cells, MEDI6383 administered to healthy nonhuman primates elicited peripheral blood CD4 and CD8 central and effector memory T-cell proliferation as well as B-cell proliferation. Together, these results suggest that OX40 agonism has the potential to enhance antitumor immunity in human malignancies.

AB - Ligation of OX40 (CD134, TNFRSF4) on activated T cells by its natural ligand (OX40L, CD252, TNFSF4) enhances cellular survival, proliferation, and effector functions such as cytokine release and cellular cytotoxicity. We engineered a recombinant human OX40L IgG4P Fc fusion protein termed MEDI6383 that assembles into a hexameric structure and exerts potent agonist activity following engagement of OX40. MEDI6383 displayed solution-phase agonist activity that was enhanced when the fusion protein was clustered by Fc gamma receptors (FcgRs) on the surface of adjacent cells. The resulting costimulation of OX40 on T cells induced NFkB promoter activity in OX40-expressing T cells and induced Th1-type cytokine production, proliferation, and resistance to regulatory T cell (Treg)mediated suppression. MEDI6383 enhanced the cytolytic activity of tumor-reactive T cells and reduced tumor growth in the context of an alloreactive human T cell:tumor cell admix model in immunocompromised mice. Consistent with the role of OX40 costimulation in the expansion of memory T cells, MEDI6383 administered to healthy nonhuman primates elicited peripheral blood CD4 and CD8 central and effector memory T-cell proliferation as well as B-cell proliferation. Together, these results suggest that OX40 agonism has the potential to enhance antitumor immunity in human malignancies.

UR - http://www.scopus.com/inward/record.url?scp=85047795212&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047795212&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-17-0200

DO - 10.1158/1535-7163.MCT-17-0200

M3 - Article

VL - 17

SP - 1024

EP - 1038

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 5

ER -